Clinical trial NCT03104491: Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
Official title: Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Acute Lymphocytic Leukemia
Keywords: allogeneic hematopoietic stem cell transplantation
donor chimerism
Lead sponsor: Case Comprehensive Cancer Center
Sponsor class: OTHER
First posted: 2017-04-07
Enrollment: 44
Sex: ALL
Minimum age (years): 16
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side effects.

The Phase II portion of this study is to see what side effects are seen with medication after transplant.

Inotuzumab ozogamicin is a combination of an antibody and chemotherapy which has been shown to have significant activity against relapsed/refractory acute lymphocytic leukemia (ALL).

Inotuzumab ozogamicin is considered experimental in this study.

Detailed description: Study Design This is a Phase I/II study of inotuzumab ozogamicin for the treatment of patients who underwent allogeneic transplantation for ALL and have a high risk of relapse. The Phase I portion of this study will be a 3+3 dose escalation trial. This is followed by a phase 2 cohort at the recommended Phase 2 dose (RP2D). Participants will receive study treatment up to 4 cycles until relapse of disease, unacceptable toxicity, or death, whichever occurs first

Phase I: Inotuzumab Ozogamicin Dosing Escalation Subjects will be assessed for safety and tolerability (including adverse events, serious adverse events, and clinical/laboratory assessments) using a continuous monitoring approach.

Phase II: Inotuzumab Ozogamicin Subjects will be assessed for safety and tolerability (including adverse events, serious adverse events, and clinical/laboratory assessments) using a continuous monitoring approach. In order to be included in the safety profile endpoint review, subjects must have received at least of 1 cycle of treatment.

Primary Objective

Phase I: To define a post hematopoietic stem cell transplantation maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of inotuzumab ozogamicin.

Phase II: To assess the efficacy of inotuzumab ozogamicin as measured by diseasefree survival (DFS) at one year.

Secondary Objective(s)

Phase I:

* To evaluate disease-free survival (DFS), nonrelapse mortality (NRM), relapse, relapse-related mortality and overall survival (OS) at 1 year.
* To determine safety profile of inotuzumab ozogamicin after transplant including the incidence of myeloid toxicity and secondary graft failure and the rate of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS).
* To determine if inotuzumab ozogamicin at these doses is effective at eradicating minimal residual disease in this cohort of participants

Phase II:

* To assess additional evidence of efficacy and safety as measured by non-relapse mortality (NRM), relapse, relapse-related mortality and overall survival (OS) at 1 year.
* To determine if inotuzumab ozogamicin at these doses is effective at eradicating MRD.
* To confirm the safety profile of inotuzumab ozogamicin therapy after transplant including myeloid toxicity, secondary graft failure, and the rate of VOD/SOS.
* To evaluate the pharmacokinetics of inotuzumab ozogamicin post allogeneic transplant

Eligibility criteria: Inclusion Criteria:

Phase 1 Inclusion Criteria

* Diagnosis of CD22-positive Acute Lymphoblastic Leukemia
* Patients who underwent an allogeneic hematopoietic stem cell transplantation from any donor source for acute lymphocytic leukemia
* Patients who are between T+40 and T+100 after allogeneic transplantation. Patients must receive their first dose of inotuzumab at or before T+100.
* Patients who have/are either:

  * Transplanted in hematologic first complete remission with evidence of minimal residual disease within 45 days of allogeneic transplantation

    ---Pre- or Post-Transplant Minimal Residual Disease defined by:

    ----Any detectable ALL (by flow cytometry, cytogenetics, or PCR techniques) as per clinical indication.
  * In second or third complete remission at the time of allogeneic transplantation
  * Treated with reduced intensity regimens or non-myeloablative conditioning regimens
  * Lymphoid blast crisis of CML
  * Are relapsed or refractory to at least 1 line of chemotherapy
  * Philadelphia-like ALL
* Patients who have evidence of donor chimerism after allogeneic transplantation.
* ECOG Performance status \< 2
* Participants must have ANC \> 1,000/µL for 3 days and platelet transfusion independence as defined as a platelet count \> 50,000/µL for 7 days.
* Able to adhere to the study visit schedule and other protocol requirements.
* Participants must have the ability to understand and the willingness to sign a written informed consent document.

Phase 2 Inclusion Criteria

* Diagnosis of CD22-positive Acute Lymphoblastic Leukemia
* Patients who underwent an allogeneic hematopoietic stem cell transplantation from any donor source for acute lymphocytic leukemia
* Patients who are between T+40 and T+100 after allogeneic transplantation
* Patients who have/are either:

  * Transplanted in hematologic first complete remission with evidence of minimal residual disease within 45 days of allogeneic transplantation

    ---Post-Transplant Minimal Residual Disease defined by:

    ----Any detectable ALL (by flow cytometry, cytogenetics, or PCR techniques) as per clinical indication.
  * In second or third complete remission at the time of allogeneic transplantation
  * Treated with reduced intensity regimens as defined per institutional standard of practice
  * Lymphoid blast crisis of CML
  * Are relapsed or refractory to at least 1 line of chemotherapy
  * Philadelphia-like ALL
* Patients who have \> 80% donor chimerism after allogeneic transplantation.
* Philadelphia chromosome positive ALL must have failed at least 1 TKI
* ECOG Performance status \< 1
* pre-transplant evaluation, see 10.1.1
* Participants must have ANC \> 1,000/µL for 3 days and platelet transfusion independence as defined as a platelet count \> 50,000/µL for 7 days.
* Able to adhere to the study visit schedule and other protocol requirements.
* Participants must have the ability to understand and the willingness to sign a written informed consent document.

Phase 1 and 2 Exclusion Criteria:

* Patients with clinical evidence of disease progression prior to enrollment
* Persistent prior treatment toxicities Grade 2 and above according to NCI CTCAE Version 4.03 (with the exception for alopecia, neuropathy, etc.)
* Patients with inadequate organ function as defined by:

  * Creatinine clearance \< 30ml/min
  * Bilirubin \> 2X institutional upper limit of normal
  * AST (SGOT) \> 2X institutional upper limit of normal
  * ALT (SGPT) \> 2X institutional upper limit of normal
* GVHD grade III or IV (for patients with a prior allogeneic transplant).
* Active acute or chronic GVHD of the liver (for patients with a prior allogeneic transplant)
* History of VOD
* Use of concomitant TKI or sirolimus
* Second active malignancy, other than non-melanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast)
* Patients with uncontrolled inter-current illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* Pregnant or breastfeeding women are excluded from this study because inotuzumab ozogamicin may be associated with the potential for teratogenic or abortifacient effects. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with inotuzumab ozogamicin, breastfeeding should be discontinued if the mother is treated with inotuzumab ozogamicin. These potential risks may also apply to other agents used in this study.
* Evidence of myelodysplasia or cytogenetic abnormality indicative of myelodysplasia on any bone marrow biopsy prior to initiation of therapy Serologic status reflecting active hepatitis B or C infection. Patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive patients will be excluded.)
* Serologic status reflecting active hepatitis B or C infection. Patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive patients will be excluded.)
* Participation in any other investigational drug study or had exposure to any other investigational agent, device, or procedure, within 21 days (or 5 half-lives, whichever is greater)
* Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
* Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds

Primary outcomes:
measure: Phase I MTD
timeFrame: Up to 112 days (16 weeks)
measure: Phase I DLTs
timeFrame: Up to 112 days (16 weeks)
measure: Phase II Median DFS
timeFrame: At 3 months after initial treatment
measure: Phase II Median DFS
timeFrame: At 6 months after initial treatment
measure: Phase II Median DFS
timeFrame: At 9 months after initial treatment
measure: Phase II Median DFS
timeFrame: At 1 year after initial treatment
measure: Phase II Median DFS
timeFrame: Post first dose of inotuzumab ozogamicin
Secondary outcomes:
measure: Phase I Median DFS
timeFrame: At 3 months after initial treatment
measure: Phase I Median DFS
timeFrame: At 6 months after initial treatment
measure: Phase I Median DFS
timeFrame: At 9 months after initial treatment
measure: Phase I Median DFS
timeFrame: At 1 year after initial treatment
measure: Phase I Median DFS
timeFrame: Post first dose of inotuzumab ozogamicin on Day 1, Cycle 1, where cycle length is 28 days
measure: Phase I NRM
timeFrame: At 3 months after initial treatment
measure: Phase I NRM
timeFrame: At 6 months after initial treatment
measure: Phase I NRM
timeFrame: At 9 months after initial treatment
measure: Phase I NRM
timeFrame: At 1 year after initial treatment
measure: Phase I NRM
timeFrame: Post first dose of inotuzumab ozogamicin on Day 1, Cycle 1, where cycle length is 28 days
measure: Phase I Relapse
timeFrame: At 3 months after initial treatment
measure: Phase I Relapse
timeFrame: At 6 months after initial treatment
measure: Phase I Relapse
timeFrame: At 9 months after initial treatment
measure: Phase I Relapse
timeFrame: At 1 year after initial treatment
measure: Phase I Relapse
timeFrame: Post first dose of inotuzumab ozogamicin on Day 1, Cycle 1, where cycle length is 28 days
measure: Phase I Relapse-related mortality
timeFrame: At 3 months after initial treatment
measure: Phase I Relapse-related mortality
timeFrame: At 6 months after initial treatment
measure: Phase I Relapse-related mortality
timeFrame: At 9 months after initial treatment
measure: Phase I Relapse-related mortality
timeFrame: At 1 year after initial treatment
measure: Phase I Relapse-related mortality
timeFrame: Post first dose of inotuzumab ozogamicin on Day 1, Cycle 1, where cycle length is 28 days
measure: Phase I Median OS
timeFrame: At 3 months after initial treatment
measure: Phase I Median OS
timeFrame: At 6 months after initial treatment
measure: Phase I Median OS
timeFrame: At 9 months after initial treatment
measure: Phase I Median OS
timeFrame: At 1 year after initial treatment
measure: Phase I Median OS
timeFrame: Post first dose of inotuzumab ozogamicin on Day 1, Cycle 1, where cycle length is 28 days
measure: Phase I Incidence of myeloid toxicity
timeFrame: At 1 year
measure: Phase I Incidence of secondary graft failure
timeFrame: At 1 year
measure: Phase I incidence of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)
timeFrame: At 1 year
measure: Phase I rate of VOD/SOS - number of participants affected
timeFrame: At 1 year
measure: Phase I - Percent of participants with grade 3 + AE/SAEs
timeFrame: At 1 year
measure: Phase II Non-relapse mortality (NRM)
timeFrame: At 3 months after initial treatment
measure: Phase II Relapse
timeFrame: At 6 months after initial treatment
measure: Phase II Relapse
timeFrame: At 9 months after initial treatment
measure: Phase II Relapse-related mortality
timeFrame: At 1 year after initial treatment
measure: Phase II Relapse-related mortality
timeFrame: Post first dose of inotuzumab ozogamicin on Day 1, Cycle 1, where cycle length is 28 days
measure: Phase II Median OS
timeFrame: At 3 months after initial treatment
measure: Phase II Median OS
timeFrame: At 6 months after initial treatment
measure: Phase II Median OS
timeFrame: At 9 months after initial treatment
measure: Phase II Median OS
timeFrame: At 1 year after initial treatment
measure: Phase II Median OS
timeFrame: Post first dose of inotuzumab ozogamicin on Day 1, Cycle 1, where cycle length is 28 days
measure: Phase II Response Rate
timeFrame: At 3 months after initial treatment
measure: Phase II Response Rate
timeFrame: At 6 months after initial treatment
measure: Phase II Response Rate
timeFrame: At 9 months after initial treatment
measure: Phase II Response Rate
timeFrame: At 1 year after initial treatment
measure: Phase II Response Rate
timeFrame: Post first dose of inotuzumab ozogamicin on Day 1, Cycle 1, where cycle length is 28 days
measure: Phase II Incidence of myeloid toxicity
timeFrame: At 1 year
measure: Phase II Incidence of secondary graft failure
timeFrame: At 1 year after initial treatment
measure: Phase I incidence of VOD/SOS
timeFrame: At 1 year
measure: Phase II rate of VOD/SOS - number of participants affected
timeFrame: At 1 year
measure: Phase II pharmacokinetic (PK) parameters - Cmax
timeFrame: At Cycle 1 Day 1 (C1D1) after 0 hours (each cycle is 28 days)
measure: Phase II pharmacokinetic (PK) parameters - Cmax
timeFrame: At Cycle 1 Day 1 (C1D1) after 1 hour (each cycle is 28 days)
measure: Phase II pharmacokinetic (PK) parameters - Cmax
timeFrame: At Cycle 1 Day 1 (C1D1) after 4 hours (each cycle is 28 days)
measure: Phase II pharmacokinetic (PK) parameters - Cmax
timeFrame: At Cycle 1 Day 7 (C1D7) (each cycle is 28 days)
measure: Phase II pharmacokinetic (PK) parameters - Cmax
timeFrame: At Cycle 2 Day 1 (C2D1) after 0 hours (each cycle is 28 days)
measure: Phase II pharmacokinetic (PK) parameters - Cmax
timeFrame: At Cycle 2 Day 1 (C2D1) after 1 hour (each cycle is 28 days)
measure: Phase II pharmacokinetic (PK) parameters - Cmax
timeFrame: At Cycle 4 Day 1 (C4D1) after 0 hours (each cycle is 28 days)
measure: Phase II pharmacokinetic (PK) parameters - Cmax
timeFrame: At Cycle 4 Day 1 (C4D1) after 1 hour (each cycle is 28 days)
measure: Phase II pharmacokinetic (PK) parameters - Ctrough
timeFrame: At Cycle 1 Day 1 (C1D1) after 0 hours (each cycle is 28 days)
measure: Phase II pharmacokinetic (PK) parameters - Ctrough
timeFrame: At Cycle1 Day 1 (C1D1) after 1 hour (each cycle is 28 days)
measure: Phase II pharmacokinetic (PK) parameters - Ctrough
timeFrame: At Cycle1 Day 1 (C1D1) after 4 hours (each cycle is 28 days)
measure: Phase II pharmacokinetic (PK) parameters - Ctrough
timeFrame: At Cycle 1 Day 7 (C1D7) (each cycle is 28 days)
measure: Phase II pharmacokinetic (PK) parameters - Ctrough
timeFrame: At Cycle 2 Day 1 (C2D1) after 0 hours (each cycle is 28 days)
measure: Phase II pharmacokinetic (PK) parameters - Ctrough
timeFrame: At Cycle 2 Day 1 (C2D1) after 1 hour (each cycle is 28 days)
measure: Phase II pharmacokinetic (PK) parameters - Ctrough
timeFrame: At Cycle 4 Day 1 (C4D1) after 0 hours (each cycle is 28 days)
measure: Phase II pharmacokinetic (PK) parameters - Ctrough
timeFrame: At Cycle 4 Day 1 (C4D1) after 1 hour (each cycle is 28 days)
Other outcomes:
Locations:
city: Westwood
country: United States
facility: The University of Kansas Cancer Center
state: Kansas
city: Boston
country: United States
facility: Dana-Farber Cancer Institute
state: Massachusetts
city: Omaha
country: United States
facility: University of Nebraska Medical Center
state: Nebraska
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
city: Cleveland
country: United States
facility: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
state: Ohio
city: Cleveland
country: United States
facility: Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
state: Ohio
city: Columbus
country: United States
facility: The James Cancer Hospital and Solove Research Institute
state: Ohio
Study officials:
affiliation: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
name: Leland Metheny, MD
role: PRINCIPAL_INVESTIGATOR
References: